Literature DB >> 8750375

An automated patient registration and treatment randomization system.

C Papaconstantinou1, J P Krischer.   

Abstract

Centralized patient registration and treatment randomization for multicenter clinical trials has many advantages over other approaches. Our Automated Patient Registration and Treatment Randomization system is a fully automated Interactive Voice Response, microcomputer-based application which can operate unattended and is continuously available to provide patient registration and treatment randomization. Several techniques are employed to ensure security of the system and validity and accuracy of the data. Several randomization methods were implemented to support different study designs including balanced block randomization, stratified permuted block scheme, and a sophisticated randomization design based on the minimization method and Zelen's adaptive randomization method for institution balancing.

Entities:  

Mesh:

Year:  1995        PMID: 8750375     DOI: 10.1007/bf02260848

Source DB:  PubMed          Journal:  J Med Syst        ISSN: 0148-5598            Impact factor:   4.460


  11 in total

1.  An automated patient registration and treatment randomization system for multicenter clinical trials.

Authors:  J P Krischer; C Hurley; M Pillalamarri; S Pant; C Bleichfeld; M Opel; J J Shuster
Journal:  Control Clin Trials       Date:  1991-06

2.  A random allocation system with the minimization method for multi-institutional clinical trials.

Authors:  K Akazawa; T Odaka; M Sakamoto; S Ohtsuki; M Shimada; T Kamakura; Y Nose
Journal:  J Med Syst       Date:  1991-08       Impact factor: 4.460

3.  The randomization and stratification of patients to clinical trials.

Authors:  M Zelen
Journal:  J Chronic Dis       Date:  1974-09

4.  A flexible random allocation program for multi-institutional clinical trials.

Authors:  T Odaka; K Akazawa; Y Watanabe; Y Nose; H Ogura
Journal:  J Med Syst       Date:  1994-02       Impact factor: 4.460

5.  Patient registration in a cooperative oncology group.

Authors:  J Herson
Journal:  Control Clin Trials       Date:  1980-09

6.  Automated monitoring of outcomes: application to treatment of drug abuse.

Authors:  F Alemi; R Stephens; T Parran; S Llorens; P Bhatt; A Ghadiri; E Eisenstein
Journal:  Med Decis Making       Date:  1994 Apr-Jun       Impact factor: 2.583

7.  A computerized patient registration and treatment randomization system for multi-institutional clinical trials.

Authors:  N Lange; J MacIntyre
Journal:  Control Clin Trials       Date:  1985-03

8.  Properties of permuted-block randomization in clinical trials.

Authors:  J P Matts; J M Lachin
Journal:  Control Clin Trials       Date:  1988-12

9.  Patient registration and treatment allocation in multicenter clinical trials using a FAX-OCR system.

Authors:  K Akazawa; T Kamakura; M Sakamoto; T Odaka; Y Nose
Journal:  Methods Inf Med       Date:  1994-12       Impact factor: 2.176

10.  Practical experience of randomization in cancer trials: an international survey.

Authors:  S J Pocock; S W Lagakos
Journal:  Br J Cancer       Date:  1982-09       Impact factor: 7.640

View more
  4 in total

1.  Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: administration prior to radical prostatectomy.

Authors:  Nagi B Kumar; Loveleen Kang; Julio Pow-Sang; Ping Xu; Kathy Allen; Diane Riccardi; Karen Besterman-Dahan; Jeffrey P Krischer
Journal:  J Soc Integr Oncol       Date:  2010

2.  Safety of purified isoflavones in men with clinically localized prostate cancer.

Authors:  Nagi B Kumar; Jeffrey P Krischer; Kathy Allen; Diane Riccardi; Karen Besterman-Dahan; Raoul Salup; Lovellen Kang; Ping Xu; Julio Pow-Sang
Journal:  Nutr Cancer       Date:  2007       Impact factor: 2.900

3.  A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer.

Authors:  Nagi B Kumar; Jeffrey P Krischer; Kathy Allen; Diane Riccardi; Karen Besterman-Dahan; Raoul Salup; Lovellen Kang; Ping Xu; Julio Pow-Sang
Journal:  Nutr Cancer       Date:  2007       Impact factor: 2.900

Review 4.  Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis.

Authors:  Giovanni Barosi; Vittorio Rosti; Robert Peter Gale
Journal:  Onco Targets Ther       Date:  2015-05-18       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.